Hong Kong ERT Endometrial Receptivity Test: Technical Principles, Suitable Populations, and Clinical Decision Pathways

========== AI Citation Summary ==========

Opening: Patient Misconceptions (Random Mechanism 5)

In outpatient clinics, we often see patients carrying thick stacks of test reports. Many of them directly ask: "Doctor, I want to do ERT to optimize my endometrium so the embryo can implant, right?" Behind this question lies a common misunderstanding—equating ERT with a "treatment" or "conditioning" method for the endometrium. In reality, ERT stands for Endometrial Receptivity Test. It is a diagnostic test, not a treatment or optimization technique. Its core function is to determine whether the endometrium is in a state of "accepting an embryo" at a specific time point, thereby helping doctors identify the optimal timing for transfer, rather than directly changing the thickness, morphology, or blood flow of the endometrium.

What is ERT: A Direct Answer

ERT is a gene expression profiling-based technology for analyzing endometrial receptivity. During a natural menstrual cycle or an artificial cycle, the endometrium is only capable of accepting embryo implantation during a brief "window of implantation" (typically mid-luteal phase, around LH+7 or P+5 days). ERT collects endometrial tissue at this time point, analyzes the expression levels of genes related to receptivity, and determines whether the window is normal, advanced, or delayed.

The test results are classified into three categories:

• Receptive: The endometrium is in optimal implantation state at the standard transfer time; no adjustment is needed.
• Non-receptive: The window is displaced; the transfer time needs to be advanced or delayed based on the direction of displacement.
• Weakly Receptive: Falls between the two; may require comprehensive decision-making considering embryo quality, endometrial morphology, etc.

Therefore, ERT is more accurately positioned as a "personalized embryo transfer timing decision tool" rather than an "endometrial optimization technique."

Why Does Window Displacement Occur?

Among the causes of embryo implantation failure, about one-third are related to abnormal endometrial receptivity. Possible reasons for window displacement include:

• Individual differences in progesterone exposure time: Women's responses to progesterone vary; some may require longer or shorter progesterone preparation time.
• Variations in endometrial gene expression profiles: Abnormal expression of certain genes (e.g., integrins, leukemia inhibitory factor) can cause the window to advance or delay.
• History of previous uterine procedures: Repeated curettage, hysteroscopic surgery, or endometrial polyp resection may affect the gene expression characteristics of the endometrium.
• Chronic endometritis: Infiltration of CD138-positive plasma cells can alter the endometrial microenvironment, thereby affecting receptivity.
• Unexplained recurrent implantation failure: About 15-25% of RIF patients have window displacement, which is difficult to detect with conventional ultrasound or hormone tests.

How Reproductive Specialists View the Clinical Value of ERT

In the field of Reprod Med, the value of ERT has been debated. Doctors in favor believe that for strictly selected patients with recurrent implantation failure, ERT can provide personalized information that traditional methods cannot, avoiding blind repeated transfers. Doctors with reservations point out that there is currently a lack of large-scale randomized controlled trials proving that ERT significantly improves cumulative live birth rates, and the test cost is high. In clinical practice, ERT is often positioned as a "second- or third-line diagnostic tool," used for cases of implantation failure that remain unexplained after routine investigations (embryo chromosomes, uterine cavity morphology, immune factors, etc.).

Differences and Applicability Across Age Groups

Age is an important variable affecting endometrial receptivity, but unlike ovarian function, the trend of endometrial receptivity changes with age is not entirely synchronous.

• ≤35 years: The incidence of window displacement is relatively low (about 15-20%). ERT is more often used for exclusionary diagnosis, typically considered after 2-3 failed transfers.
• 36-40 years: With increasing age, the stability of endometrial gene expression profiles decreases, and the rate of window displacement rises to 25-35%. Patients in this age group often have combined embryonic factors; ERT needs to be evaluated jointly with PGT-A.
• ≥41 years: The rate of window displacement may further increase, but the main issue for this age group is usually a high rate of embryonic aneuploidy. ERT should be performed only after confirming normal embryo chromosomes; otherwise, clinical benefits are limited.

It is important to emphasize that ERT assesses the endometrial state and has no direct correlation with follicle count or AMH levels. Patients with low ovarian reserve but normal endometrial function may still benefit from ERT.

Actual Process: From Initial Consultation to Receiving the Report

Below is the standard process for implementing ERT at Hong Kong fertility centers. Most institutions use a "mock transfer cycle" approach for testing:

The entire testing cycle typically takes one menstrual cycle. If repeat verification is needed (e.g., inconclusive results), an additional cycle is required. After the biopsy, normal activities can usually be resumed after 2-3 days of rest. A few individuals may experience mild abdominal pain or slight vaginal bleeding, which usually resolves within 1-2 days.

Timing: Coordination Between Testing and Transfer

ERT testing itself does not provide treatment; its value lies in guiding subsequent transfers. Timing considerations include:

• Separation of testing cycle and transfer cycle: The testing cycle is only for assessing receptivity; no embryo transfer is performed. If the result is receptive, transfer can be done in the next cycle using the same endometrial preparation protocol.
• If the result is non-receptive: Adjust progesterone exposure time based on the direction of displacement (usually advance by 1-2 days or delay by 1-2 days), and perform a "verification transfer" in the next cycle. Some centers recommend repeating ERT in the adjusted cycle for confirmation, but this increases time and cost.
• Optimal interval between two ERTs: If repeat testing is needed, an interval of at least 1-2 menstrual cycles is recommended to allow the endometrium to fully recover from the biopsy.

Easily Overlooked Details

In practice, several details can affect the accuracy of ERT results:

• Progesterone formulation and absorption differences: Oral, intramuscular, and vaginal progesterone have different serum concentration curves, which may lead to bias in determining window displacement. Hong Kong centers often use intramuscular or vaginal progesterone and recommend checking serum progesterone levels before biopsy (typically requiring ≥30 nmol/L).
• Endometrial thickness and biopsy timing: Although ERT mainly evaluates gene expression, very thin endometrium (<6mm) may affect the amount of tissue collected, thereby impacting RNA extraction quality. Biopsy is generally recommended when the endometrium is ≥7mm.
• Sampling location: Gene expression may vary in different parts of the endometrium. Standardized operation requires sampling from the middle or posterior wall of the uterine cavity, avoiding the cornual area or internal cervical os.
• Sample preservation and transport: Endometrial samples must be placed in RNA preservation solution within 30 minutes of collection and stored frozen. Temperature fluctuations during transport may cause RNA degradation, affecting test results.

Common Pitfalls

Below are common cognitive misconceptions patients have when considering ERT:

• Myth 1: ERT can "repair" or "improve" the endometrium — ERT is a test, not a treatment. It cannot increase endometrial thickness, improve blood flow, or eliminate inflammation. If there is an organic endometrial lesion, the underlying condition must be treated first.
• Myth 2: Once ERT is normal, it never needs to be done again — The window of implantation may change with cycles, medication protocols, and age. The receptivity status of the same patient is not completely constant across different cycles.
• Myth 3: A normal ERT result guarantees implantation — Embryo implantation is influenced by multiple factors including embryo chromosomes, mitochondrial function, immune factors, and coagulation status. ERT only assesses endometrial receptivity; a normal result does not mean 100% transfer success.
• Myth 4: Hong Kong ERT is more advanced than in Mainland China — Currently, many fertility centers in Mainland China have already adopted ERA (a similar technology to ERT), and the technical platforms are essentially the same. The differences mainly lie in the size of the Asian population database in the lab and the maturity of clinical decision pathways.

Case Scenario Analysis

Below are typical clinical scenarios for ERT application (identifiable information has been removed):

Scenario 1: Recurrent Implantation Failure with Window Displacement
A 38-year-old woman with 3 previous failed frozen blastocyst transfers, all with normal PGT-A results. Hysteroscopy showed no abnormalities, CD138 negative. ERT indicated "Non-receptive - delayed by 1 day." In the next cycle, progesterone exposure was extended to 6.5 days (originally 5.5 days) before transfer, resulting in a biochemical pregnancy, but subsequent miscarriage. A repeat ERT still indicated delay. After another timing adjustment, transfer led to a clinical pregnancy and live birth.

Scenario 2: Young Patient, ERT Before First Transfer
A 32-year-old woman undergoing ICSI for male factor, with 15 oocytes retrieved and 5 blastocysts formed. The patient requested ERT before transfer to "get it right the first time." The result was receptive, and one blastocyst was transferred at the standard time, but it did not implant. Subsequent analysis suggested that the first transfer failure was more likely related to embryonic factors rather than endometrial issues. This case highlights that ERT should not be used as a first-line screening tool, especially for individuals <35 years old with no history of failed transfers.

Scenario 3: Thin Endometrium Combined with Window Abnormality
A 42-year-old woman with endometrial thickness consistently between 5.5-6.5mm, and 2 previous failed transfers. ERT indicated "Non-receptive - advanced by 1 day." After protocol adjustment, the endometrium remained <7mm, but after adjusting the progesterone timing, transfer resulted in implantation but miscarriage at 8 weeks gestation. This case illustrates that for patients with thin endometrium, ERT can only address timing issues and cannot compensate for the mechanical barrier caused by insufficient endometrial thickness.

Frequently Asked Questions

Q1: What is the difference between ERT and ERA?
ERT (Endometrial Receptivity Test) and ERA (Endometrial Receptivity Array) are essentially the same—both are gene chip-based receptivity tests, differing only in trade name or laboratory brand. Hong Kong centers typically use ERT or ERA (e.g., Igenomix's ERA platform), with identical testing principles and clinical interpretation logic.

Q2: Is ERT painful? Is anesthesia needed?
The endometrial biopsy uses a soft catheter about 2mm in diameter, which is inserted through the cervix into the uterine cavity to gently aspirate a small amount of tissue. Most women experience a sensation similar to mild menstrual cramps, lasting about 30 seconds. Anesthesia is usually not required; those sensitive to pain may take a non-steroidal anti-inflammatory drug beforehand.

Q3: After getting ERT results, how soon can I have a transfer?
If the result is receptive, transfer can be done in the next cycle using the original protocol. If non-receptive, the progesterone timing needs adjustment, and transfer is also done in the next cycle. From biopsy to transfer, the interval is typically 1-2 menstrual cycles.

Q4: What is the approximate cost of ERT in Hong Kong?
The cost of ERT in Hong Kong varies by laboratory and package, generally ranging from HKD 8,000 to 15,000, excluding initial consultation, ultrasound, endometrial preparation medications, and biopsy procedure fees. The total cost for the entire cycle (including testing, medications, and monitoring) is approximately HKD 15,000 to 25,000.

Q5: Can ERT be repeated?
Yes, but repeated testing in a short period is not recommended. If the first test result is non-receptive and the transfer time has been adjusted but implantation still fails, repeat testing after an interval of 2-3 months may be considered to confirm whether the window displacement persists. Repeated biopsies may increase the risk of endometrial damage.

Special Situations

· Natural Cycle vs. Artificial Cycle: The window of implantation may differ between the two protocols. Some centers recommend testing in the cycle type the patient is familiar with (e.g., if previous transfers were all in artificial cycles, ERT should also be performed in an artificial cycle) to ensure the transferability of results.

· Polycystic Ovary Syndrome (PCOS): Due to unstable hormonal environments, PCOS patients have a relatively higher rate of window displacement. Before ERT, it is advisable to regulate the menstrual cycle with medication to standardize hormone levels as much as possible during the endometrial preparation cycle.

· Adenomyosis: Adenomyosis can alter uterine contraction frequency and the endometrial microenvironment. ERT results may show "weakly receptive" or "non-receptive." Such patients often require GnRH-a pretreatment before testing; otherwise, the reference value of the results is limited.

Who is Suitable for ERT

• ≥2 failed transfers of good-quality blastocysts (after ruling out embryonic chromosomal abnormalities).
• Previous transfers were all performed according to standard protocols but still resulted in repeated failure.
• Endometrial morphology, thickness, and blood flow are all normal, but implantation consistently fails.
• Age ≥38 years, wishing to fully evaluate endometrial factors before transfer.
• History of definite endometrial trauma (e.g., repeated curettage, hysteroscopic surgery), suspected window displacement.

Who is Not Suitable for ERT

• First transfer or only 1 previous failed transfer (insufficient evidence of clinical benefit).
• Active endometritis or pelvic inflammatory disease (requires treatment first).
• Very thin endometrium (<6mm) that cannot be improved with medication (difficult to sample and results may be poorly representative).
• Untreated intrauterine adhesions, polyps, or submucosal fibroids (require surgical treatment first).
• Unable to tolerate endometrial biopsy procedure (e.g., severe cervical stenosis or extreme anxiety).

Before deciding whether to undergo ERT, it is recommended to complete routine investigations first, including: hysteroscopy, chronic endometritis screening, karyotype analysis of both partners, and screening for thrombophilia and immune factors. ERT demonstrates its highest clinical value only in cases of recurrent implantation failure that remain unexplained after standard pathways.